Active Ingredient(s): Tafamidis Meglumine
FDA Approved: * May 3, 2019
Pharm Company: * FOLDRX PHARMS
Category: Genetic Disorders

Tafamidis, sold under the brand names Vyndaqel and Vyndamax,[3] is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis. It can be used to treat both hereditary forms, familial amyloid cardiomyopathy and familial amyloid polyneuropathy, as well as wild-type transthyretin amyloidosis, which formerly was called senile systemic amyloidosis. It works by stabilizing the quaternary structure of the protein transthyretin. In people ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Vyndaqel 20 mg Oral Capsule, Liquid Filled
NDC: 0069-1975
Pfizer Laboratories Div Pfizer Inc
NDC: 0069-8729
Pfizer Labs Division of Pfizer Inc.

Related Brands

Drugs with the same active ingredients